GM-CSF

Type: Keyphrase

Name: GM-CSF

First reported May 15 2013 - Updated May 16 2013 - 1 reports

Positive Phase II Results Reported for Ovarian Cancer Vaccine

Time to recurrence more than double that of standard treatment (May 15)In a randomized phase II trial, a tumor-based personalized cancer vaccine (FANG; Gradalis, Inc.) elicited an immune response and delayed the time to recurrence in patients with advanced-stage ... [Published PT Community - May 15 2013]

Entities: cancer vaccine, Ovarian Cancer, Patient, Phase II, Vaccine

First reported May 15 2013 - Updated May 15 2013 - 1 reports

American Society of Clinical Oncology

Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting

THOUSAND OAKS, Calif."The data that we are presenting at ASCO demonstrate great progress with our effort to develop treatments that will help patients with advanced cancers," said Sean E. HarperMeeting delegates who visit Amgen's booth will also have ... [Published Bio-Medicine - May 15 2013]

Entities: American Society of Clinical Oncology, Amgen Inc, Skin Cancer, Blinatumomab, Sean E Harper

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Characterization of pathogenic human monoclonal autoantibodies against GM-CSF [Immunology]

The origin of pathogenic autoantibodies remains unknown. Idiopathic pulmonary alveolar proteinosis is caused by autoantibodies against granulocyte–macrophage colony-stimulating factor (GM-CSF). We generated 19 monoclonal autoantibodies against GM-CSF ... [Published Bionity.com - May 15 2013]

Entities: GM-CSF, Immunology, idiopathic

First reported May 07 2013 - Updated May 07 2013 - 1 reports

Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors

Product DescriptionThe new Competitive Intelligence Report Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis of the product portfolios and development pipelines of ten major classes of therapeutic ... [Published MarketResearch.com - May 07 2013]

Entities: Therapeutic Proteins Inc, thrombopoietin, G-CSF, GM-CSF, Research & Development

First reported May 06 2013 - Updated May 06 2013 - 1 reports

Colorectal cancer-specific gene - viral drugs

The present invention discloses a kind of colorectal cancer specific genes - viral therapy drugs. Adenovirus to its natural promoter of the early genes E1A colorectal cancer-specific promoter CEA substituted constitute an oncolytic adenovirus, which carry ... [Published PatBase - May 06 2013]

Entities: colorectal, Colorectal Cancer, Drugs, Adenovirus

First reported May 04 2013 - Updated May 04 2013 - 1 reports

A little miracle, 20 years in the making

Source: adelaidenow HER arrival is a breakthrough for IVF treatment but for parents Rachel and Con Coussiounelos, baby Elena is simply the answer to their parenthood dreams. The two-week-old is the first baby born in Australia using a pioneering EmbryoGen ... [Published Herald Sun - May 04 2013]

Entities: In Vitro Fertilisation, Embryo, Miscarriage, Fertility

First reported Apr 23 2013 - Updated Apr 23 2013 - 2 reports

Research and Markets: Competitor Analysis: G-CSF and GM-CSF Business Wire

DUBLIN--(BUSINESS WIRE)-- Research and Markets has announced the addition of the "Competitor Analysis: G-CSF and GM-CSF" report to their offering. The present Competitive Intelligence Report about G-CSF and GM-CSF product portfolios and R&D pipelines ... [Published Yahoo! Finance - Apr 23 2013]

Entities: G-CSF, GM-CSF, Research & Development, Pipeline, neutropenia

First reported Apr 22 2013 - Updated Apr 22 2013 - 1 reports

HIV Vaccines – Novel approaches, funding, and clinical studies

The afternoon session of Day One at the World Vaccine Congress USA 2013 got underway, with Dr Rick King, VP Vaccine Design at IAVI , chairing the session. He spoke about the hope and excitement surrounding broadly neutralizing antibodies, and introduced ... [Published Terrapinn - Apr 22 2013]

Entities: Vaccine, HIV/AIDS, vectors, GeoVax

First reported Apr 22 2013 - Updated Apr 22 2013 - 1 reports

Competitor Analysis: G-CSF and GM-CSF

The present Competitive Intelligence Report about G-CSF and GM-CSF product portfolios and R&D pipelines provides a competitor evaluation in the field of G-CSF & GM-CSF branded products in regulated markets and products in non-regulated markets, biosimilars ... [Published PipelineReview - Apr 22 2013]

Entities: G-CSF, GM-CSF, Research & Development, Pipeline, neutropenia

First reported Apr 14 2013 - Updated Apr 14 2013 - 1 reports

Plymouth student earns Science Fair grand award

Plymouth resident Mackenzie Zierau, a student at Mercy High School in Farmington Hills, was one of six students to receive a grand award at the Science and Engineering Fair of Metropolitan Detroit.Filed UnderPlymouth resident Mackenzie Zierau, 15, was ... [Published Canton Observer - Apr 14 2013]

Entities: GM-CSF, macrophage, Detroit (Michigan, United States), cytokine, White Blood Cell

First reported Mar 22 2013 - Updated Mar 22 2013 - 1 reports

Good News in Oncology: Oncolytic Virus Therapy

The last few days have brought some good news on some unusual approaches to cancer therapy. First off was Amgen's report that they'd seen positive results in advanced melanoma using a modified HSV treatment. This is technology that they brought in by ... [Published In the Pipeline - Mar 22 2013]

Entities: Oncolytic virus, Oncology, BioVex Inc, GM-CSF

First reported Mar 21 2013 - Updated Mar 21 2013 - 1 reports

Amgen's phase III talimogene laherparepvec trial in melanoma meets primary endpoint

Amgen has reported top-line results from the phase III trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment with subcutaneous granulocyte-macrophage ... [Published PharmaBiz - Mar 21 2013]

Entities: Skin Cancer, GM-CSF, Phase III, primary endpoint

Quotes

"The data that we are presenting at ASCO demonstrate great progress with our effort to develop treatments that will help patients with advanced cancers" said Sean E Harper

Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting [Published Bio-Medicine - May 15 2013]

...validation of Pexa-Vec as an active immunotherapeutic agent," said Laurent Fischer, M D , president and chief executive officer of Jennerex. "Furthermore, the association between the development of an immune response against a patient's own cancer and a patient's survival suggest that this activity has the potential to be clinically relevant. We look forward to validating the clinical potential of Pexa-Vec across our ongoing Phase 2 program in liver, colorectal and kidney cancers."

Jennerex Announces Science Translational Medicine Publication Highlighting Pexa-Vec's Ability to ... [Published Individual.com - May 15 2013]

...of Pexa-Vec as a potential treatment for this lethal disease," said Laurent Fischer, M D , president and chief executive officer of Jennerex. "We look forward to announcing top-line data from our TRAVERSE trial by the end of this year and to bring Pexa-Vec to the market as soon as possible."

Jennerex Granted FDA Orphan Drug Designation for Pexa-Vec in Hepatocellular Carcinoma (HCC) Top-L ... [Published PR inside - May 08 2013]

..."It's delightful to meet baby Elena and see the benefits of this work with a family like Rachel and Con's," she said. "It's one thing to work in a lab but it really does bring it home when you see the human face of this kind of research. It's very rewarding." Fertility SA is the first clinic in Australia to offer the treatment in a clinical setting and it's anticipated it will be rolled out next year, pending...

A little miracle, 20 years in the making [Published Herald Sun - May 04 2013]

More Content

sort by: Date \| Relevance
Amgen Highlights Data To Be Presented At Americ... [Published Bio-Medicine - May 15 2013]
Positive Phase II Results Reported for Ovarian ... [Published PT Community - May 15 2013]
Jennerex Announces Science Translational Medici... [Published Individual.com - May 15 2013]
Characterization of pathogenic human monoclonal... [Published Bionity.com - May 15 2013]
Jennerex Granted FDA Orphan Drug Designation fo... [Published PR inside - May 08 2013]
Peptides specific for human blood outgrowth end... [Published PharmCast - May 08 2013]
Competitor Analysis: Therapeutic Proteins – Bio... [Published MarketResearch.com - May 07 2013]
Colorectal cancer-specific gene - viral drugs [Published PatBase - May 06 2013]
2013 Will be a Banner Year for GeoVax - Analyst... [Published Quote.com Hong Kong - May 06 2013]
A little miracle, 20 years in the making [Published Herald Sun - May 04 2013]
Undervaluation Of Vical's Full Pipeline Allows ... [Published Seeking Alpha - May 03 2013]
Biotechnology: Strong Fundamentals Are The Basi... [Published Seeking Alpha - May 03 2013]
Bavarian Nordic Agrees on Interim Analysis with... [Published Asian Hospital & Healthcare Management - Apr 29 2013]
Patent Issued for Herpes Simplex Virus Expressi... [Published Equities.com - Apr 24 2013]
Research and Markets: Competitor Analysis: G-CS... [Published Yahoo! Finance - Apr 23 2013]
Research and Markets: Competitor Analysis: G-CS... [Published Business Wire - Apr 23 2013]
Research and Markets: Competitor Analysis: G-CS... [Published Reuters - Apr 23 2013]
Research and Markets: Competitor Analysis: G-CS... [Published Business Wire Professional Services News - Apr 23 2013]
HIV Vaccines – Novel approaches, funding, and c... [Published Terrapinn - Apr 22 2013]
Competitor Analysis: G-CSF and GM-CSF [Published PipelineReview - Apr 22 2013]
U.S. Patents Awarded to Inventors in Alabama (A... [Published Equities.com - Apr 20 2013]
CBAP Functions as a Novel Component in Chemokin... [Published Elites TV - Apr 19 2013]
There Is A Lot To Like About Celldex Therapeutics [Published Seeking Alpha - Apr 17 2013]
JCI early table of contents for April 15, 2013 [Published EurekAlert! - Apr 15 2013]
2 Oncology Biotechs For The Future [Published Seeking Alpha - Apr 14 2013]
Plymouth student earns Science Fair grand award [Published Canton Observer - Apr 14 2013]
Biotechs Stocks with Staggering Profit Potential [Published Market Oracle - Apr 09 2013]
Vaxil Reports Positive Results From a Phase I/I... [Published Yahoo! Finance - Apr 09 2013]
Jennerex Announces Presentation of Data Demonst... [Published Live-PR.com - Apr 09 2013]
Regulation of Porcine Plasmacytoid Dendritic Ce... [Published Elites TV - Apr 09 2013]